A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat
Status:
Completed
Trial end date:
2016-08-24
Target enrollment:
Participant gender:
Summary
Multicenter, double-blind, placebo controlled, Phase 3 study to determine the safety and
tolerability of oral tecovirimat, an anti orthopoxvirus compound, in subjects.
Phase:
Phase 3
Details
Lead Sponsor:
SIGA Technologies
Collaborator:
Biomedical Advanced Research and Development Authority